Dyslipidemia is a common lipid abnormality in diabetic individuals effecting 30-60% adults all over the world. This study aimed to evaluate the therapeutic efficacy of amla fruit powder against diabetic dyslipidemia using animal models. The male Wistar rats procured for the study were divided into four groups randomly: G1 (negative control group), G2 (positive control group), G3 (rats receiving amla powder at 5% of their diet), and G4 (rats receiving amla powder at 7% of their diet). Diabetes was induced in rats using streptozotocin at a dose of 65 mg/kg, leading to significant disruption in the lipid biomarkers such as total cholesterol, LDL, HDL, and triglycerides. The amla treatment demonstrated a remarkable ameliorative effect on serum lipid biomarkers. A significant decrease in total cholesterol, LDL and triglyceride was observed while a significant increase occurred in the HDL level. Conclusively, amla fruit effectively alleviated streptozotocin-induced diabetic dyslipidemia in rats.
Umber Younas (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: